- St John's wort has the strongest single-supplement evidence for mild-to-moderate depression — a Cochrane review of 29 trials (5,489 patients) found it superior to placebo and comparable to standard antidepressants — but it carries the highest interaction risk of any supplement covered, including serotonin syndrome risk with antidepressants.
- L-theanine (200–400 mg/day) and saffron have promising, lower-risk evidence for stress/anxiety and mild depression respectively, but both need larger independent trials.
- Magnesium and vitamin D are adequacy tools, not mood cures: the VITAL-DEP trial found vitamin D3 did not reduce depression risk over a median 5.3 years, and magnesium's anxiety evidence is rated poor quality.
- Kava carries rare but serious liver-injury risk (including liver-transplant cases) and NCCIH says it doesn't clearly help generalized anxiety disorder — a poor risk/benefit trade.
- Homeopathic anxiety remedies, "happy pill" blends, casual 5-HTP stacking, and broad CBD mental-health claims are the biggest hype-to-evidence gaps in this category.
Ingredient evidence review · Funding and conflict traced
The most defensible supplements for stress, anxiety, or mild depressive symptoms are adjuncts, not cures: St John’s wort has the strongest depression signal but the most dangerous interaction profile; saffron, L-theanine, ashwagandha, and EPA-rich omega-3 have promising but limited roles; magnesium and vitamin D mainly make sense when intake or status is low. Popular “happy pills,” homeopathic anxiety remedies, CBD mental-health overclaims, 5-HTP stacks, kava anxiety products, and broad adaptogen blends either have weak evidence, safety problems, or marketing that outruns clinical proof (NCCIH St John’s wort, Cochrane omega-3 depression review, NCCIH kava).
Table of contents
- Evidence summary
- Bottom line: what is worth considering
- The evidence tiers
- Proven or promising ingredients
- Popular supplements with weak, mixed, or no useful evidence
- All forms and types
- What works and what does not
- Risks and all side effects
- All interactions
- Frequently asked questions
- Sources
Evidence summary
| Ingredient / claim | Evidence | Funding / conflict tracing | Verdict |
|---|---|---|---|
| St John’s wort for mild-to-moderate depression | Cochrane reviewed 29 trials with 5,489 patients and found St John’s wort extracts superior to placebo, similarly effective to standard antidepressants, and with fewer side effects than standard antidepressants in trials. | Cochrane public summary does not show funding for every included trial; herbal-product trial fields have manufacturer and regional bias risks, so the efficacy conclusion is paired with strict interaction warnings. | Works, but high-risk Cochrane |
| St John’s wort safety | NCCIH warns it can interact with antidepressants and other serotonin-affecting drugs in ways that may be serious, and interaction reviews describe CYP and P-glycoprotein mechanisms. | NCCIH is a government health-information source; interaction reviews are PubMed-indexed pharmacology literature with no sales incentive for St John’s wort. | Highest interaction burden NCCIH / PubMed interaction review |
| Omega-3 EPA-rich supplements for depression | Cochrane found insufficient high-certainty evidence for omega-3 in major depressive disorder; NCCIH says any effect may be too small to be meaningful. | Cochrane and NCCIH are relatively independent; many omega-3 trials use donated products or nutraceutical involvement, so mood claims are downgraded. | Mixed adjunct Cochrane / NCCIH omega-3 |
| Ashwagandha for stress or sleep | NCCIH says some preparations may be effective for insomnia and stress, but long-term safety conclusions cannot be made and rare liver injury cases have been linked to supplements. | Many ashwagandha trials are product-specific or industry-adjacent; NCCIH has no product-sales incentive, and liver-injury case reports are clinical safety evidence. | Promising but safety-limited NCCIH / liver injury case series |
| L-theanine for stress/anxiety | A systematic review of human RCTs concluded 200–400 mg/day may reduce stress and anxiety in people exposed to stressful conditions, while calling for larger and longer studies. | Review authors are academic; some included trials involve branded ingredients, so the claim is limited to short-term adjunctive stress support. | Promising low-burden adjunct L-theanine review |
| Saffron for mild-to-moderate depression | Meta-analyses report saffron more effective than placebo and non-inferior to tested antidepressants in small RCTs, but authors call for larger trials and replication beyond concentrated research groups. | Some saffron research and reviews disclose supplement-company or nutraceutical ties; geographic clustering and small samples downgrade certainty. | Promising, not definitive saffron meta-analysis / saffron review |
| Magnesium for anxiety/stress | A systematic review found suggestive benefit for subjective anxiety in vulnerable samples but concluded evidence quality was poor and better RCTs are needed. | Academic review; funding details were limited in the PubMed record, so the claim is treated as suggestive. | Suggestive only magnesium review |
| Vitamin D for depression prevention | VITAL-DEP found vitamin D3 supplementation did not significantly reduce depression risk, recurrence, or mood-score change over median 5.3 years. | NIH-funded trial with product donations disclosed in the broader VITAL program; null results reduce concern that product donation inflated benefit. | Doesn’t prevent depression broadly VITAL-DEP |
| Homeopathic anxiety remedies | A systematic review found evidence for homeopathy in anxiety and anxiety disorders was limited, contradictory, underpowered, or insufficient for firm conclusions; another psychiatry review found efficacy not shown for anxiety or stress. | Homeopathy journals and CAM-focused literature may have field allegiance incentives; findings are still weak even within that evidence base. | No useful evidence homeopathy anxiety review / psychiatry homeopathy review |
| Kava for anxiety | NCCIH says kava supplements may help anxiety after several weeks but do not appear helpful for generalized anxiety disorder symptoms; rare severe or fatal liver injury cases are a major safety issue. | NCCIH and NIH ODS are government sources; kava clinical trials and product variability create uncertainty. | Mixed evidence, serious risk NCCIH kava / NIH ODS kava |
| CBD for anxiety/depression overclaims | Recent reviews suggest CBD may reduce anxiety in some trial contexts, but RCTs are small, heterogeneous, and contradictory, and further trials are needed. | CBD research has strong commercial incentives and product heterogeneity; no strong independent basis supports broad “anxiety cure” or depression claims. | Overclaimed CBD RCT review / CBD meta-analysis |
| 5-HTP for depression | Cochrane review found few reliable studies despite possible benefit signals and concluded clinical usefulness is limited because effective and safer alternatives exist. | Old, small trials and incomplete safety evidence downgrade confidence; serotonin-syndrome concern is mechanistically plausible and reviewed in pharmacology literature. | Overhyped and interaction-prone Cochrane 5-HTP review / 5-HTP safety review |
Bottom line: what is worth considering
The strongest supplement evidence is not the same as the safest choice. St John’s wort has a real signal for mild-to-moderate depression in trials, but it is often the wrong self-care choice because it can interact with antidepressants, anticoagulants, oral contraceptives, transplant medicines, HIV medicines, seizure medicines, digoxin, cancer medicines, and many other drugs through serotonin effects, CYP induction, and P-glycoprotein induction (NCCIH St John’s wort, St John’s wort interaction review).
For a lower-risk supplement discussion, L-theanine is plausible for acute stress, saffron is plausible for mild depressive symptoms, EPA-rich omega-3 is mixed but reasonable when dietary intake is low or cardiovascular context also matters, and magnesium/vitamin D should be framed as deficiency or adequacy tools rather than guaranteed mood treatments (L-theanine review, saffron meta-analysis, Cochrane omega-3 depression review, NIH ODS magnesium, VITAL-DEP).
Text version of this infographic
- Tier 1: St John’s wort works for some mild-to-moderate depression trials, but the interaction burden is high.
- Tier 2: Saffron, L-theanine, and selected ashwagandha preparations are promising adjuncts with important evidence and safety limits.
- Tier 3: Magnesium, vitamin D, and EPA-rich omega-3 are best framed around adequacy, deficiency, diet pattern, or adjunctive context rather than cure claims.
- Tier 4: Homeopathy, “happy pill” blends, CBD cure claims, casual 5-HTP stacks, and do-it-yourself kava are not supported as reliable mental-health treatments.
The evidence tiers
Tier 1: strongest evidence but highest interaction risk
St John’s wort is the clearest example of why “natural” does not mean “safe.” Cochrane found benefit in depression trials, while NCCIH warns about serious interactions with antidepressants and other serotonin-affecting drugs and about compromised effects of other medicines (Cochrane St John’s wort, NCCIH St John’s wort). The editorial verdict is narrow: it may be considered only for mild-to-moderate depression when a qualified clinician or pharmacist has ruled out medication, pregnancy, bipolar-spectrum, transplant, HIV, cancer-treatment, seizure, anticoagulant, and contraceptive risks.
Tier 2: promising adjuncts with limits
Saffron has positive depression meta-analyses, including one reporting significant effects versus placebo and non-inferiority to tested antidepressants in mild-to-moderate depression, but the evidence base is small and needs more independent long-term trials (saffron meta-analysis). L-theanine has a short-term stress/anxiety signal, with one systematic review suggesting 200–400 mg/day may help people exposed to stressful conditions, but the authors call for larger and longer studies (L-theanine review). Ashwagandha may help some stress and insomnia outcomes, but NCCIH states long-term safety is not established and rare liver injury cases have been reported (NCCIH ashwagandha).
Tier 3: adequacy and deficiency tools
Magnesium may help subjective anxiety in vulnerable samples, but the systematic review found the evidence poor and in need of better RCTs (magnesium review). Vitamin D supports bone and mineral physiology, but VITAL-DEP did not support vitamin D3 for broad depression prevention in adults aged 50+ without clinically relevant depressive symptoms at baseline (VITAL-DEP, NIH ODS vitamin D). Omega-3 is biologically plausible and useful for some non-mood indications, but Cochrane says high-certainty evidence is insufficient for major depressive disorder and NCCIH says any depression effect may be too small to be meaningful (Cochrane omega-3 depression review, NCCIH omega-3).
Tier 4: popular claims to downgrade or reject
Homeopathic anxiety remedies do not have reliable evidence for anxiety disorders: one systematic review found limited and contradictory evidence, and a psychiatry review found efficacy not shown for anxiety or stress (homeopathy anxiety review, homeopathy psychiatry review). Kava has a mixed anxiety signal but carries rare severe liver-injury risk, and NCCIH says kava does not appear helpful for generalized anxiety disorder symptoms (NCCIH kava). CBD has early anxiety signals in small heterogeneous trials, but reviews call for better RCTs and do not justify broad anxiety/depression cure marketing (CBD RCT review, CBD meta-analysis). 5-HTP is overhyped because the Cochrane review found few reliable studies and stated clinical usefulness is limited, while pharmacology reviews discuss serotonin syndrome and other safety issues (Cochrane 5-HTP review, 5-HTP safety review).
Proven or promising ingredients
Omega-3 EPA: mixed depression evidence, plausible adjunct
EPA and DHA are long-chain omega-3 fatty acids found in fish oil, krill oil, cod liver oil, algal oil, and some prescription products, while ALA from flax/chia/walnuts converts inefficiently to EPA/DHA, with NIH ODS reporting conversion rates typically below 15% (NIH ODS omega-3). For depression, the best conservative conclusion is “possible adjunct, not primary treatment,” because Cochrane found insufficient high-certainty evidence for omega-3 in major depression and NCCIH says any effect may be too small to be meaningful (Cochrane omega-3 depression review, NCCIH omega-3).
St John’s wort: effective enough to be dangerous
St John’s wort should be written about like an active drug, not a wellness tea. Cochrane found trial benefits for depression, but NCCIH warns about serious serotonin-related interactions and drug-effect compromise, and PubMed-indexed reviews describe pharmacokinetic interactions involving CYP enzymes and P-glycoprotein (Cochrane St John’s wort, NCCIH St John’s wort, St John’s wort interaction review).
Ashwagandha: stress signal plus liver and pregnancy caution
Ashwagandha is most defensible as a short-term stress or insomnia adjunct using studied preparations, not as a broad anxiety/depression treatment. NCCIH says some preparations may be effective for insomnia and stress, but long-term safety conclusions cannot be reached and rare liver injury cases have been linked to ashwagandha supplements (NCCIH ashwagandha).
L-theanine: short-term stress support
L-theanine has a cleaner, narrower claim than many mood supplements: it may help manage stress and anxiety responses in stressful conditions. The human RCT systematic review concluded 200–400 mg/day may assist stress and anxiety reduction, but also said larger and longer clinical studies are needed before using it as a therapeutic agent (L-theanine review).
Saffron: promising for mild-to-moderate depression
Saffron has one of the better herbal depression signals after St John’s wort, but certainty remains limited by small trials, replication needs, and possible supplement-industry ties. A meta-analysis found saffron more effective than placebo and non-inferior to tested antidepressants in mild-to-moderate depression, while another review called for larger trials outside heavily represented research settings and with longer follow-up (saffron meta-analysis, saffron MDD review).
Text version of this infographic
| Ingredient | Most defensible role | Non-negotiable caveat |
|---|---|---|
| St John’s wort | Mild-to-moderate depression. | High interaction burden; do not combine with many medicines without professional review. |
| L-theanine | Stress response and situational anxiety support. | Evidence is short-term and not a treatment for severe anxiety. |
| Saffron | Mild-to-moderate depressive symptoms. | More independent long-term replication needed. |
| Ashwagandha | Stress and sleep support. | Rare liver injury and pregnancy/thyroid/immune cautions. |
Popular supplements with weak, mixed, or no useful evidence
Homeopathic anxiety remedies
Homeopathic anxiety remedies should not be presented as evidence-based anxiety treatment. A systematic review concluded evidence for anxiety and anxiety disorders was limited, contradictory, underpowered, or insufficient for firm conclusions, and a psychiatry-focused review found efficacy not shown for anxiety or stress (homeopathy anxiety review, homeopathy psychiatry review).
“Happy pill” blends
“Happy pill,” “mood cure,” and “anxiety cure” blends commonly combine serotonergic ingredients, sedating herbs, adaptogens, amino acids, and vitamins without testing the exact blend in high-quality clinical trials. The evidence problem is not that every component is useless; the problem is that a proprietary combination can inherit every interaction risk while having none of the single-ingredient evidence.
Kava
Kava is not a clean win. NCCIH states kava supplements may help anxiety but may need weeks to work, do not appear helpful for generalized anxiety disorder symptoms, and have been linked to rare cases of severe or fatal liver injury (NCCIH kava). NIH ODS notes reports of hepatitis, cirrhosis, liver failure, and a liver-transplant case in kava-associated safety reports (NIH ODS kava).
Adaptogen hype
Ashwagandha has some evidence, but broad adaptogen claims often extrapolate from stress markers, animal studies, proprietary trials, or traditional-use narratives to claims about depression and anxiety disorders. If a blend contains ashwagandha, rhodiola, ginseng, schisandra, holy basil, mushrooms, or sedating herbs, treat it as a multi-drug exposure and ask for exact human RCT evidence on that exact formula.
CBD mental-health overclaims
CBD may have an anxiety signal in some contexts, but reviews describe small samples, heterogeneous disorders, varied doses, and contradictory findings, which is not enough to support broad “CBD cures anxiety/depression” claims (CBD RCT review, CBD meta-analysis). CBD also has clinically relevant interaction potential through drug-metabolizing enzymes, and a review of CBD interactions notes interactions with medications and substances require caution (CBD interactions review).
5-HTP
5-HTP is a serotonin precursor, which makes it pharmacologically active rather than harmless. A Cochrane review found possible benefit signals but few studies of sufficient quality and limited clinical usefulness, while a pharmacology review discusses serotonin syndrome and eosinophilia-myalgia syndrome safety issues (Cochrane 5-HTP review, 5-HTP safety review).
All forms and types
| Ingredient | Commercial forms / types | What matters clinically | Evidence verdict |
|---|---|---|---|
| Omega-3 | Fish oil, krill oil, cod liver oil, algal EPA/DHA, ethyl ester, triglyceride/re-esterified triglyceride, phospholipid forms, ALA oils such as flax/chia. | EPA/DHA are the relevant long-chain forms; ALA conversion to EPA/DHA is limited; cod liver oil also contains vitamins A and D. | Mixed for depression NIH ODS |
| St John’s wort | Standardized extracts, capsules/tablets, teas, tinctures, combination mood formulas. | Trial results are extract-specific; teas/tinctures may not match studied hypericin/hyperforin profiles; hyperforin-rich products may have stronger interaction potential. | Works but high-risk Cochrane |
| Ashwagandha | Root powder, root extract, root+leaf extract, standardized withanolide extracts, gummies, sleep/stress blends. | Evidence is preparation-specific; root and root+leaf products are not interchangeable; long-term safety is uncertain. | Promising for stress/sleep NCCIH |
| L-theanine | Pure L-theanine capsules/tablets, green tea-derived products, caffeine+theanine formulas, drinks and powders. | Pure L-theanine evidence should not be used to justify high-caffeine energy products; caffeine can worsen anxiety in some people. | Promising short-term PubMed |
| Saffron | Whole stigma, stigma extract, petal extract, standardized crocin/safranal extracts, combination mood formulas. | Depression trials usually use standardized extracts or defined doses; culinary saffron use is not equivalent to trial dosing. | Promising PubMed |
| Magnesium | Glycinate, citrate, oxide, chloride, malate, taurate, threonate, topical magnesium, multi-mineral blends. | Elemental magnesium dose and GI tolerance matter; magnesium binds some medicines; kidney function matters more than form hype. | Suggestive for anxiety PubMed / NIH ODS |
| Vitamin D | D3/cholecalciferol, D2/ergocalciferol, calcifediol, drops, tablets, softgels, sprays, fortified foods, high-dose regimens. | Correct deficiency under appropriate testing/clinical context; excess can cause hypercalcemia; not proven for broad depression prevention. | Deficiency tool VITAL-DEP |
| Kava | Water extracts, ethanolic/acetonic extracts, capsules, tinctures, teas, instant powders, standardized kavalactone products. | Product part, cultivar, extraction solvent, alcohol use, and contamination/adulteration may affect liver risk. | Mixed/risky NCCIH |
| CBD | Isolate, broad-spectrum, full-spectrum, oils, gummies, capsules, drinks, vapes, topical products. | Products vary widely; THC contamination, drug interactions, sedation, and liver-enzyme effects matter; mental-health claims are overbroad. | Overclaimed PubMed |
| 5-HTP | Capsules/tablets, tryptophan blends, sleep/mood blends, formulas with SAMe, St John’s wort, saffron, or SSRIs. | Serotonin precursor; stacking with serotonergic agents raises risk; evidence quality is weak. | Overhyped Cochrane/PMC |
What works and what does not
| Claim | Verdict | Evidence | Key caveat |
|---|---|---|---|
| St John’s wort helps mild-to-moderate depression. | WORKS | Cochrane trial review. | Serious interactions make it unsuitable for many people. |
| Saffron helps mild-to-moderate depressive symptoms. | PROMISING | Meta-analyses of small RCTs. | Need larger independent long-term trials. |
| L-theanine helps stress/anxiety response. | PROMISING | Systematic review of human RCTs. | Not a treatment for anxiety disorders by itself. |
| Ashwagandha helps stress/sleep. | PROMISING | NCCIH summary of selected preparations. | Liver, pregnancy, thyroid, immune, and sedative cautions. |
| Omega-3 treats major depression. | MIXED | Cochrane says high-certainty evidence is insufficient. | May be more rational when intake is low or EPA-rich formula is used as adjunct. |
| Magnesium calms anxiety for everyone. | INSUFFICIENT | Suggestive but poor-quality evidence. | Best framed as adequacy/deficiency support. |
| Vitamin D prevents depression in adults generally. | DOESN’T | VITAL-DEP null result. | Correct deficiency; do not promise mood prevention. |
| Homeopathic anxiety remedies work. | DOESN’T | Systematic reviews find limited/no anxiety-stress efficacy. | Can delay real care. |
| Kava is a safe natural anxiety fix. | DOESN’T | Mixed benefit plus rare severe liver injury. | Avoid in liver risk, alcohol use, sedatives, pregnancy/lactation. |
| CBD cures anxiety or depression. | DOESN’T | Small heterogeneous trials; better RCTs needed. | Drug interactions and product variability matter. |
| 5-HTP is a safe antidepressant alternative. | DOESN’T | Few reliable studies; safety concerns include serotonin syndrome. | Avoid serotonergic stacking. |
Text version of this infographic
- Homeopathic anxiety remedies: limited and contradictory evidence; not a reliable anxiety treatment.
- CBD cure claims: small, heterogeneous, mixed trials and meaningful drug-interaction concerns.
- Kava as a safe anxiety fix: possible anxiety benefit in some contexts but rare severe liver injury risk.
- 5-HTP mood stacks: weak evidence and serotonin syndrome concern, especially with serotonergic medicines or other mood supplements.
- Evaluation rule: require exact ingredient, exact form, exact dose, exact human evidence, and exact interaction check.
Risks and all side effects
| Ingredient | Common side effects | Rare but serious risks | Who should avoid or use only with clinician input | Independent source |
|---|---|---|---|---|
| Omega-3 EPA/DHA | Fishy aftertaste, bad breath, heartburn, nausea, loose stools. | Bleeding concerns with anticoagulants/antiplatelets; high-dose atrial fibrillation concern in some literature. | Bleeding disorders, anticoagulant/antiplatelet users, atrial fibrillation history, fish/shellfish allergy, surgery planning. | NIH ODS omega-3 |
| St John’s wort | Diarrhea, dizziness, trouble sleeping, restlessness, skin tingling, photosensitivity. | Serotonin syndrome; loss of effectiveness of critical medicines; mania in bipolar-spectrum vulnerability. | Anyone taking antidepressants, oral contraceptives, anticoagulants, immunosuppressants, HIV medicines, cancer medicines, seizure medicines, digoxin, or many chronic medicines; pregnancy/lactation; bipolar disorder. | NCCIH |
| Ashwagandha | Digestive upset, diarrhea, nausea, vomiting, drowsiness. | Liver injury; acute-on-chronic liver failure in vulnerable people has been reported in a case series. | Pregnancy, lactation, liver disease, autoimmune disease, thyroid disease, sedative users, immunosuppressant users. | NCCIH / PMC case series |
| L-theanine | Sleepiness, headache, GI discomfort are possible; safety data are limited. | Long-term risk profile not well established. | Pregnancy/lactation, sedative users, people with low blood pressure or multiple CNS-active medicines. | PubMed review |
| Saffron | Nausea, headache, dizziness, dry mouth, appetite change. | High-dose toxicity; possible serotonergic and bleeding cautions; pregnancy concern at high doses. | Pregnancy/lactation, bipolar-spectrum symptoms, serotonergic medicine users, bleeding-risk patients until safety is clarified. | saffron safety review |
| Magnesium | Diarrhea, nausea, abdominal cramping. | High-dose toxicity, low blood pressure, heart rhythm problems, respiratory depression in severe toxicity, especially kidney impairment. | Kidney disease, older adults with polypharmacy, antibiotic/bisphosphonate users. | NIH ODS magnesium |
| Vitamin D | Nausea, constipation, weakness, thirst, frequent urination when excessive. | Hypercalcemia, kidney stones, kidney injury, dangerous calcium-related heart rhythm problems. | Kidney disease, high calcium, granulomatous disease, hyperparathyroidism, thiazide or digoxin users. | NIH ODS vitamin D |
| Kava | Digestive upset, headache, dizziness, drowsiness. | Severe liver injury, liver failure, death or transplant in rare reports. | Liver disease, alcohol use, sedatives, pregnancy/lactation, hepatotoxic medicines, surgery planning. | NCCIH kava / NIH ODS kava |
| CBD | Drowsiness, diarrhea, appetite/weight changes, fatigue. | Liver enzyme elevations and drug interactions; impairment when combined with sedatives or alcohol. | Liver disease, pregnancy/lactation, sedative users, anti-seizure medicine users, anticoagulant users, multiple-medicine users. | CBD adverse effects review / CBD interaction review |
| 5-HTP | Nausea, diarrhea, dizziness. | Serotonin syndrome; eosinophilia-myalgia syndrome concerns reviewed in the literature. | Anyone taking SSRIs, SNRIs, MAOIs, triptans, tramadol, linezolid, lithium, St John’s wort, SAMe, or other serotonergic products; pregnancy/lactation; bipolar-spectrum symptoms. | Cochrane/PMC / safety review |
All interactions
| Medication / condition / substance | Interacting supplement(s) | Severity | Mechanism / concern | Action |
|---|---|---|---|---|
| SSRIs, SNRIs, MAOIs, tricyclics, mirtazapine, trazodone, triptans, tramadol, linezolid, lithium, MDMA or serotonergic substances | St John’s wort, 5-HTP, SAMe blends, caution with saffron | Avoid | Serotonin-related adverse effects, including serotonin syndrome. | Do not combine without clinician/pharmacist clearance. |
| Oral contraceptives, transplant immunosuppressants, HIV medicines, cancer medicines, seizure medicines, digoxin, many antidepressants | St John’s wort | Avoid | CYP and P-glycoprotein induction can lower drug exposure and effectiveness. | Avoid unless a prescriber actively manages the interaction. |
| Warfarin, DOACs, aspirin, clopidogrel, NSAID-heavy use, bleeding disorders | Omega-3, St John’s wort, saffron, CBD | Caution/monitor | Bleeding risk, altered anticoagulant effect, or metabolism interactions. | Clinician/pharmacist review before use. |
| Benzodiazepines, Z-drugs, opioids, sedating antihistamines, antipsychotics, alcohol | Kava, CBD, ashwagandha, L-theanine, sedating blends | Avoid stacking | Additive sedation, impaired coordination, CNS depression. | Avoid alcohol and sedative combinations unless medically supervised. |
| Tetracycline antibiotics, quinolone antibiotics, bisphosphonates | Magnesium | Separate doses | Mineral binding reduces medication absorption. | Separate by prescriber/pharmacist instructions. |
| Thiazide diuretics, digoxin, high-dose calcium | Vitamin D | Monitor | Hypercalcemia risk; calcium shifts may worsen digoxin toxicity risk. | Use labs and clinician guidance. |
| Liver disease, elevated liver enzymes, hepatotoxic medicines | Kava, ashwagandha, CBD, multi-herb blends | Avoid or specialist review | Rare liver injury or liver-enzyme effects. | Avoid self-use; stop and seek care for jaundice, dark urine, itching, pale stools, or upper abdominal pain. |
| Kidney disease | Magnesium, high-dose vitamin D, mineral blends | Medical supervision | Reduced clearance and electrolyte toxicity. | Do not self-dose. |
| Autoimmune disease or immunosuppressants | Ashwagandha, immune “adaptogen” blends | Caution/avoid | Potential immune modulation. | Ask treating clinician. |
| Thyroid disease or thyroid medication | Ashwagandha | Monitor/avoid DIY | Possible thyroid hormone effects. | Use only with thyroid monitoring. |
| Bipolar disorder, mania/hypomania history, psychosis | St John’s wort, 5-HTP, saffron, stimulant/adaptogen blends | Avoid DIY | Mood activation, destabilization, or delayed psychiatric treatment. | Psychiatric review first. |
| Pregnancy, lactation, trying to conceive | St John’s wort, ashwagandha, kava, 5-HTP, CBD, high-dose saffron | Avoid unless clinician-directed | Safety uncertainty or specific harm signals. | Use pregnancy-qualified medical advice only. |
Text version of this infographic
- Serotonergic medicines: avoid St John’s wort and 5-HTP unless clinician-directed; use caution with serotonergic blends and saffron stacks.
- Critical medicines: St John’s wort can lower drug effectiveness through CYP/P-glycoprotein induction.
- Blood thinners: check omega-3, saffron, St John’s wort, and CBD before use.
- Sedatives or alcohol: avoid stacking kava, CBD, ashwagandha, L-theanine, and sleep blends.
- Liver/kidney disease, pregnancy, bipolar symptoms: professional review before any mood supplement.
Funding and influence check
| Evidence area | Money / influence risk | How this article handled it |
|---|---|---|
| St John’s wort | Some trials are older, extract-specific, and regionally clustered; herbal manufacturers benefit if results are generalized to all products. | Reported efficacy narrowly and paired every positive statement with serious interaction warnings. |
| Saffron | Small trials, geographic clustering, and some nutraceutical-company disclosures create replication risk. | Called promising, not proven as a replacement for treatment. |
| Ashwagandha | Many trials use branded extracts or supplement-company involvement; social media demand can amplify weak claims. | Used NCCIH and liver-injury literature to balance benefits with safety limits. |
| CBD | Large commercial market, product heterogeneity, and influencer claims create strong incentive to overstate benefits. | Downgraded to overclaimed until larger independent RCTs support specific uses. |
| Homeopathy | Field-allegiance risk exists, but even CAM-focused reviews do not provide reliable anxiety efficacy. | Classified as no useful evidence for anxiety treatment. |
| Multi-ingredient “happy pill” blends | Proprietary formulas can hide dose logic and rely on ingredient halo effects. | Required exact formula trials; otherwise downgraded. |
Frequently asked questions
What supplement works best for depression?
St John’s wort has the strongest herbal evidence for mild-to-moderate depression, but it also has the strongest interaction warning and is unsafe with many medicines (Cochrane St John’s wort, NCCIH St John’s wort). Saffron is promising but less definitive, and no supplement should replace professional care for severe depression.
What supplement works best for anxiety?
No supplement is a first-line replacement for evidence-based anxiety treatment. L-theanine has a plausible short-term stress/anxiety signal, magnesium evidence is suggestive but weak, and kava has safety problems that make casual use hard to justify (L-theanine review, magnesium anxiety review, NCCIH kava).
Is St John’s wort safer than antidepressants?
No. St John’s wort may have fewer side effects than antidepressants in some trials, but it can dangerously interact with antidepressants and reduce the effectiveness of many critical medicines (Cochrane St John’s wort, NCCIH St John’s wort).
Are homeopathic anxiety remedies evidence-based?
No reliable evidence supports homeopathic remedies as effective anxiety treatment. A systematic review found evidence limited, contradictory, underpowered, or insufficient for firm conclusions, and a psychiatry review found homeopathy did not show efficacy for anxiety or stress (homeopathy anxiety review, homeopathy psychiatry review).
Is CBD proven for anxiety or depression?
CBD is not proven as a broad anxiety or depression treatment. Recent reviews show possible anxiety signals but emphasize small, heterogeneous, and sometimes contradictory trials, and CBD has drug-interaction concerns (CBD RCT review, CBD interaction review).
Is kava worth trying for anxiety?
Kava is difficult to recommend for self-directed anxiety use because any possible benefit is offset by rare but serious liver injury reports. NCCIH says kava may help anxiety in some contexts but does not appear helpful for generalized anxiety disorder symptoms and has been linked to severe or fatal liver injury (NCCIH kava).
Can I combine several mood supplements?
Combining mood supplements increases uncertainty and can create additive serotonin, sedation, bleeding, liver, or drug-metabolism risks. Avoid stacking St John’s wort, 5-HTP, SAMe, saffron, CBD, kava, ashwagandha, sedatives, alcohol, or antidepressants unless a clinician/pharmacist has reviewed the exact formula and medicines.
Does vitamin D help if I am deficient?
Correcting vitamin D deficiency is important for health, but vitamin D should not be marketed as a universal depression-prevention supplement. VITAL-DEP found vitamin D3 did not significantly prevent depression or improve mood scores over median 5.3 years in adults aged 50+ without clinically relevant depressive symptoms at baseline (VITAL-DEP, NIH ODS vitamin D).
- Severe?Care first
- Exact form?No blends
- Human RCTs?Not anecdotes
- Conflicts?Trace money
- Interactions?Medication check
Text version of this infographic
- Are symptoms severe or unsafe? If yes, professional care comes before supplements.
- Is the exact form and dose identified? Avoid vague blends and proprietary “mood matrices.”
- Are there human randomized trials or high-quality reviews? Do not rely on anecdotes, animal data, or influencer claims.
- Were funding and conflicts checked? Product-sponsored evidence is downgraded.
- Were interactions checked? Review medicines, pregnancy, liver/kidney disease, bipolar risk, sedatives, and blood thinners.
Sources
- WHO — Depressive disorder (depression)
- WHO — Anxiety disorders
- Cochrane — St John’s wort for treating depression
- NCCIH — St John’s Wort: Usefulness and Safety
- Izzo and Ernst — St John’s wort drug interactions. PubMed
- Cochrane — Omega-3 fatty acids for depression in adults
- NCCIH — Omega-3 Supplements: What You Need To Know
- NIH ODS — Omega-3 fatty acids fact sheet
- NCCIH — Ashwagandha: Usefulness and Safety
- Philips et al. Ashwagandha-induced liver injury case series. PMC
- Williams et al. L-theanine stress and anxiety systematic review. PubMed
- Marx et al. Saffron for mild-to-moderate depression meta-analysis. PubMed
- Lopresti and Drummond. Saffron and major depressive disorder. PubMed
- Safety and efficacy of saffron for mild-to-moderate depression. PubMed
- Boyle et al. Magnesium supplementation for subjective anxiety and stress. PubMed
- NIH ODS — Magnesium fact sheet
- Okereke et al. Vitamin D3 and depression risk, VITAL-DEP. PubMed
- NIH ODS — Vitamin D fact sheet
- NCCIH — Kava: Usefulness and Safety
- NIH ODS — Kava safety information
- Pilkington et al. Homeopathy for anxiety and anxiety disorders. PubMed
- Homeopathic treatments in psychiatry systematic review. PubMed
- The impact of cannabidiol treatment on anxiety disorders: RCT review. PubMed
- Therapeutic potential of CBD in anxiety disorders: systematic review/meta-analysis. PubMed
- CBD adverse effects and toxicity. PMC
- CBD interactions with medications and substances. PMC
- Cochrane/PMC — Tryptophan and 5-HTP for depression
- Turner et al. 5-HTP safety review. PubMed